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Oseltamivir phosphate is extensively metabolized in the ex vivo human placenta model, and the transplacental passage of the
metabolite oseltamivir carboxylate is incomplete. Objective. To evaluate the metabolism and transplacental transfer of oseltamivir
(Tamiﬂu) in the ex vivo human placental model. Study Design. Perfusion studies were performed in six placentas from term,
uncomplicated deliveries. Concentrations of oseltamivir phosphate (OP) that were 5-6 fold, 20–30 fold, and 600–800 fold above
the therapeutic peak were tested, as neither OP nor its active metabolite, oseltamivir carboxylate (OC), could be detected at
near-therapeutic concentrations. The transplacental transfer and accumulation of OC were assessed using the 14C antipyrine
reference method. Results. OP was extensively metabolized to OC. In the 4 placentas with the highest concentration of OP, OC
had a mean clearance index of 0.13 ± 0.08, suggesting that transplacental passage occurs at a relatively low rate. Measurable
fetal accumulation occurred in the two placentas with the highest initial concentrations. Conclusions. Oseltamivir phosphate was
extensively metabolized in the ex vivo model. Transplacental transfer of the metabolite was incomplete and accumulation was
minimal.
Copyright © 2008 Kevin C. Worley et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Oseltamivir phosphate (Tamiﬂu, Roche), (3R, 4R, 5S)-4-
acetylamino-5-amino-3(1-ethylpropoxy)-1cyclohexene-1ca-
rboxylic acid, ethyl ester, phosphate (1 : 1) is an antiviral
agent with activity against both inﬂuenza A and B [1].
Oseltamivir is one of two members of the class of antivirals
known as neuraminidase inhibitors whose proposed mec-
hanism of action is to interfere with the release of
progeny viral particles from infected host cells, thereby
preventing local spread of infection [2]. Both oseltamivir
and zanamivir (Relenza, GlaxoSmithKline) are approved
for the treatment of inﬂuenza A and B; however, only
oseltamivir is administered orally and is approved for
postexposure chemoprophylaxis [1].
Globally, inﬂuenza remains one of the most signiﬁcant
causes of febrile respiratory morbidity and mortality, as it
aﬀects approximately 20% of the world’s population annu-
ally [2]. In the United States alone, epidemics of inﬂuenza
are thought to be responsible for up to 36,000 deaths per
year [3]. Immunoprophylaxis remains the cornerstone of
controlling the spread of inﬂuenza, and annual vaccination
is recommended for all persons who are at increased risk
for complications from inﬂuenza infection [3]. Among those
included within these high-risk groups, pregnant women are
of particular interest because of the implications of maternal
illness to her unborn child. The risks for severe illness and
death related to inﬂuenza infection are known to be elevated
in pregnant women, a concept historically supported by
the disproportionate number of inﬂuenza-related maternal
deaths during the pandemics of 1918 and 1957 [4]. Based on
these risks, the CDC now recommends universal vaccination
for pregnant women, regardless of gestational age. Despite
these recommendations, however, the annual number of
hospitalizations for seasonal inﬂuenza infection in pregnant
women remains high [5, 6].
In addition to seasonal inﬂuenza, signiﬁcant attention
has recently been given to the particularly pathogenic strain
of avian inﬂuenza, H5N1. A number of cases of human
infection with H5N1 have been reported with a high case
fatality rate, including a report of a pregnant woman who
succumbed rapidly to viral pneumonia caused by H5N1 [7].2 Infectious Diseases in Obstetrics and Gynecology
There is growing concern that H5N1 will cause the next
inﬂuenza pandemic, yet no vaccine exits for this virulent
strain of the virus [8].
There exists, therefore, great clinical interest in antiviral
agents that may reduce the burden of annual clinical
disease, and oseltamivir, in particular, may also have activity
against avian inﬂuenza [9]. Unfortunately, limited data exist
concerning the use of oseltamivir in pregnancy. The purpose
of this study was to evaluate the metabolism and maternal-
fetal transplacental passage of oseltamivir in the ex vivo
human placental model.
2. MATERIALS AND METHODS
Term placentas (n = 6) were collected from either vaginal or
otherwise uncomplicated cesarean deliveries in accordance
with the University of Texas Southwestern Medical Center
Institutional Review Board for Human Studies Guidelines,
and they were transported to the laboratory in normal saline
immediately after delivery. Both oseltamivir phosphate and
its active metabolite oseltamivir carboxylate were obtained,
with permission, from Roche (Basel, Switzerland).
Thesinglecotyledonplacentalperfusionsystemwasused
as described by Schneider and Huch [10]. A fetal artery
and vein on the chorionic plate were cannulated with 3.0F
and 5.0F catheters, respectively. The fetal circulation was
established by gently perfusing Eagle’s minimal essential
media including 3% bovine albumin and 0.5units/mL of
heparin (Sigma Chemical Co, St. Louis, Mo, USA). The
cotyledon was initially examined for vascular integrity.
The isolated cotyledon and adjoining placental tis-
sue were transferred to a temperature-controlled chamber
(37
◦C) where the fetal circulation was perfused with media
at 4.5–5.0mL/min for 20 minutes to stabilize the pressure
and determine if the cotyledon had a vascular leak. In
general, we could not detect leaks of less than 2cc/min;
however, volumes into and out of the system were carefully
measured, and when a change in volume was noted, the
system was presumed to have a leak. The ﬁnal pressure was
generally about 35mmHg. If the cotyledon failed to reach
a stable baseline pressure or was found to have a leak, it
was discarded. Finally, the maternal side of the catheterized
cotyledon was sealed, and three 18-guage needles were
inserted into the intervillous space of the selected cotyledon
to reestablish the maternal circulation. Maternal ﬂow rate
was at 17mL/min.
The maternal and fetal compartments each contained
150cc of Eagle’s minimal essential medium (pH 7.2–7.4),
which was aerated with 95% oxygen and 5% carbon dioxide.
Maternal-fetal transfer was performed with oseltamivir
phosphate (OP) by adding the drug to the maternal circu-
lation at concentrations that were approximately 5-6 fold
(n = 2), 20–30 fold (n = 2), and 700–800 fold (n = 2) above
the therapeutic peak. Supratherapeutic concentrations were
studied, as neither OP nor its active metabolite, oseltamivir
carboxylate (OC), could be detected when near-therapeutic
concentrations were used.
In each of the 6 placentas that met study criteria,
experiments were conducted for the ﬁrst hour with both
circulations open to determine the clearance index (CI) of
the drug. During this portion of the experiment, 2–5cc of
outﬂowsampleswerecollectedfromthevenoussidesofboth
the maternal and fetal circulations every ten minutes. Then,
both systems were closed and recirculated for one additional
hourtodeterminelevelsofaccumulation.Thecollectedﬂuid
aliquots were then analyzed. The transport fraction of 14C
antipyrine was used as a reference compound to determine
the CI of oseltamivir carboxylate. A transport fraction of
more than 30% for antipyrine was deemed representative of
maternal-fetal circulatory match [10].
The high-pressure liquid chromatography (HPLC) assay
of the prodrug oseltamivir phosphate is a modiﬁcation of the
proceduredescribedbySweenyetal.[11].TheHPLCanalysis
was carried out on Waters Associates instruments (Milford,
Mass, USA) and consisted of a preparation of a standard
curve to breach the range of oseltamivir used. All specimens
and standards were extracted in aliquots of 0.5mL. To
each tube was added 0.5mL of acetonitrile to precipitate
blood and other proteins. The samples and standards were
mixed and centrifuged at 800x gravity for 10 minutes, and
the clear supernatant was injected into a Supelcosil LC-18-
B Column (Supelco Chromatography Products, Bellefonte,
Pa, USA). The HPLC conditions consisted of a mobile
phase of 50% acetonitrile and 50% 0.01M ammonium
acetate. The sensitivity of the instrument was 0.005AU at a
wavelength of 230nm. The ﬂow rate of the mobile phase was
1.5mL/min, and an injection volume of 40 microliters was
used. The retention time of oseltamivir was 7.5 minutes. All
concentrations of the drug were determined by measuring
peak height of the extracted standards and perfusates. The
HPLC method wasvalidated; the reproducibility data arenot
shown.
The HPLC method for assaying the metabolite oselt-
amivir carboxylate was as follows. The drug was dissolved
in water and diluted to anticipated therapeutic concen-
trations. The placental perfusion samples were aliquoted
in 1.0mL samples and made alkaline with 20mL of 5N
NaOH. The samples were then added to the C18 Sep-pack
column (Waters Associate, Milford, Mass, USA) that had
been activated by the following procedure: 1mL of 0.1M
PO4 buﬀer (pH 6.1) was added to 0.1gm/50cc of 2-(N-
morphalino) ethane sulfonic acid (MES), an ion buﬀer;
this mixture was then washed through the column and the
p r o c e d u r er e p e a t e d .O n em Lo fm e t h y la l c o h o lw a sa d d e d
to the column and washed, followed by two washings of
the phosphate buﬀer containing MES. After the sample
had been pulled through by vacuum, the column was
washed with 1mL of PO4 buﬀer containing MES. At this
time the active metabolite was washed oﬀ of the Sep-pack
column with phosphate buﬀer containing 5% acetonitrile.
The HPLC assay parameter consisted of a 717 autosampler,
a 486 detector, a 515 pump (Waters Associate instruments,
Milford, Mass, USA), and a 0.1 millivolt Linear 1200 chart
recorder (Scientiﬁc Marketing, Houston, Tex, USA). The
HPLC column was a Supelcosil LC-18-DB, 25cm × 4.6mm,
5μm column (Supelco, Bellefonte, Pa, USA). Seventy-ﬁve
microlitersofextractedsampleswereinjectedintothesystem
with a ﬂow rate of 2.5mL/min at detection settings ofKevin C. Worley et al. 3
Table 1: Mean maternal and fetal concentrations of oseltamivir phosphate and oseltamivir carboxylate from 6 term placental cotyledons
perfused with supratherapeutic concentrations of oseltamivir phosphate.
Maternal (ng/ml) Fetal (ng/ml)
Placenta OP
∗ OC OP OC
1 320 (5x) ND ND ND
2 400 (6x) ND ND ND
3 1300 (20x) 86 ND 4.3
4 2160 (30x) 140 30 5
5 51000 (780x) 90 7300 9
6 54000 (830x) 96 3300 2.4
∗concentration relative to therapeutic dose in parentheses.
ND = nondetectable.
0.01AU,220nmwavelengthwithametaboliteretentiontime
of about 6.4 minutes. The mobile phase was 5% acetonitrile
in 0.1M PO4 buﬀer (pH 6.1) containing 0.5gm of MES
per 500mL. The standard curve was validated for within
and between batch reproducibility and the lower limit of
quantitation determined.
3. RESULTS
The recovery of OP and OC by HPLC analysis was greater
than 80%. The minimum sensitivities for detection were
30ng/mL and 2.4ng/mL for OP and OC, respectively.
Previous pharmacokinetic studies of oseltamivir have
determined that the peak plasma concentrations after a
75mg twice-daily dosing regimen are 65.2ng/mL for OP
and 348ng/mL for OC [1] .I no u rs t u d y ,w ew e r eu n a b l et o
detect either the prodrug or its active metabolite when levels
in the perfusate were either in the therapeutic range or 5-6
fold above the therapeutic range. At higher concentrations
(20- to 830-fold above the therapeutic range), we were able
to detect OC in both the maternal and fetal circulation
(Table 1). The results presented in the table represent the
mean concentrations from the samples assayed in the open
circulation. Mean concentrations were used to ensure that
the values were representative of a steady state. The mean
clearanceindexinthesesupratherapeuticconcentrationswas
0.13 ± 0.08. In a recirculated (i.e., closed-closed) system,
OC accumulated in the fetal circulation only in the two
placentas with the highest initial concentrations of OP; the
mean accumulation in these cases was 17.0 ± 14.6ng.
4. DISCUSSION
The pharmacokinetics of oseltamivir have been studied in
geriatric and pediatric populations, and treatment trials
have demonstrated the safety and eﬃcacy of the drug
in these populations, both of which are considered high-
risk for complicated inﬂuenza-related illness [2]. Little is
known, however, regarding the pharmacokinetics or safety
of oseltamivir in pregnancy. Oseltamivir is classiﬁed as
Pregnancy Category C, as animal studies have suggested that
an adverse eﬀect on the fetus may exist, but there have been
no well-controlled studies conducted in humans. Animal
studies [12]f o re ﬀects on embryo-fetal development have
been conductedwith rats and rabbits whowere administered
oseltamivir by the oral route. Relative doses were up to 100
times the human exposure in the rat and up to 50 times
in the rabbit. Fetal exposure was seen in both species, and
there was a dose-dependant increase in the incidence of
minor skeletal deformities. The individual incidences of each
anomaly, however, remained within the background rates of
occurrence of the species studied. Although we are unable to
examine the fetal eﬀects of exposure to oseltamivir in the ex
vivo model, we are not aware of any other study evaluating
the metabolism and transplacental passage of oseltamivir in
the human placenta.
Oseltamivir phosphate is administered orally as an ethyl
ester prodrug which is extensively converted by hepatic
esterasestotheactivecompoundoseltamivircarboxylate[1].
Approximately 80% of an orally administered dose reaches
the circulation as OC, and the metabolite has excellent
penetration into tissues such as the lung, nasal mucosa, and
middle ear [13]. The peak plasma concentrations are lower
and the half-life is shorter for OP than for OC, respectively,
so the placenta of a pregnant woman would presumably
be exposed to higher sustained levels of OC than the
prodrug. Since, however, no pharmacokinetic studies have
been conducted in pregnant subjects, we chose to examine
the prodrug in our placental perfusion model. Subsequently
measuringtheconcentrationsofthemetaboliteinthemater-
nal and fetal circulations enabled us to estimate both the
extent to which the drug was metabolized and the eﬃciency
with which the metabolite transfers from one compartment
toanother.Oseltamivircarboxylatedoesnotundergofurther
metabolism in vivo and is excreted unchanged in urine [13];
therefore, the clearance index obtained from our model is
likely a valid estimate of maternal-fetal transfer.
Our results suggest that OP is extensively metabolized to
OC in the ex vivo human placental model. Although hepatic
esterases are primarily responsible for the hydrolysis of OP
to OC in vivo, serum esterases can also eﬀect signiﬁcant
conversion of the prodrug to the metabolite. Lindegardh
et al. [14] examined the ex vivo metabolism of oseltamivir
and found that up to 31.8% of the prodrug was converted
into the metabolite after 4 hours of exposure to human
serum. This conversion was not completely arrested even
when the samples were placed on ice, but it was inhibited
by the addition of the esterase inhibitor dichlorvos. In our4 Infectious Diseases in Obstetrics and Gynecology
model, most residual fetal blood is removed by perfusing
the fetal artery and vein after initial cannulation; however,
the “ﬂushing” of the intervillous space is less complete in
the maternal circulation, and it is possible that the perfusate
was exposed to residual maternal serum and the proteins
contained therein. The placenta itself, however, also contains
esterase activity. Histochemical analysis of the human pla-
centa has demonstrated a high concentration of “nonspe-
ciﬁc” esterase in the trophoblast of the villi and a variable
concentration in the villous cores [15] .W ea r eu n a b l et o
determine in our study whether OP was metabolized to OC
byserumesterases,placentalesterasesorboth,butourresults
suggest that this conversion was extensive.
The transplacental transfer of a substance is regulated
by a number of variables, including molecular weight, ionic
charge, concentration in the maternal plasma, maternal
blood ﬂow rate, protein binding, and placental metabolism
[16]. Most compounds with a molecular weight less than
500 daltons diﬀuse readily through the placenta [16]. Given
that oseltamivir carboxylate has a molecular weight of
312.4 daltons and has low protein binding (3%), [1]i t
was somewhat surprising that the transplacental passage
of this compound was incomplete in the ex vivo model.
Although OC is not thought to be further metabolized,
another metabolite of OP hasbeen identiﬁed by Sweeny et al.
[11]. They described a novel metabolite which was recovered
from the urine, plasma, and tissue samples of rats who were
administered OP by the oral route. The (R)-ω-carboxyilic
acid metabolite was identiﬁed by HPLC and NMR analysis;
and it was the second most abundant metabolite in these
specimens after the active neuraminidase inhibitor. In the
present study, we did not evaluate for the presence of
ω-hydroxylated products, and if placental metabolism of
OP yielded these metabolites, it is possible—depending on
the distribution of the products of hydrolysis—that our
estimated clearance index of OC is falsely low. Importantly,
however, very high concentrations of OP had to be studied
before either the prodrug or the active metabolite could be
detected, and accumulation in the fetal compartment was
minimal.
Oseltamivir is the only orally bioavailable antiviral
medication that is recommended for chemoprophylaxis and
treatment of inﬂuenza in the United States, and the demand
for this drug is likely to increase. The adamantane class
of antivirals, including amantadine and rimantadine, has
activity against inﬂuenza A, but suﬃcient resistance has
developed in contemporary strains of inﬂuenza that the
CDC has recommended avoiding the use of these agents
until susceptibility can be reestablished [3]. Resistance to
oseltamivir, conversely, has been observed infrequently, and
the resistant strains identiﬁed in clinical samples appear
to have reduced infectivity and potential for transmission
[9]. Oseltamivir has also demonstrated eﬃcacy—both in
vitro and in animal models—against the H5N1 and H9N2
strains of avian inﬂuenza for which no eﬀective vaccine
exists [9]. To date, the World Health Organization has
reported 329 conﬁrmed cases of avian inﬂuenza A/(H5N1)
with 201 deaths (61% case-fatality rate), and concern that
a mutated H5N1 could result in the next pandemic has
caused a number of nations and international agencies to
generate a stockpile of oseltamivir [17]. The potential global
importance of this medication is quite evident, but it is
unfortunate that such a paucity of data exists concerning its
use in pregnant women, especially since they are more likely
to develop serious complications from inﬂuenza infection
than their nonpregnant counterparts.
5. CONCLUSIONS
Our study suggests that oseltamivir phosphate is extensively
metabolized in the ex vivo human placental model. The
active metabolite oseltamivir carboxylate was identiﬁed in
the maternal and fetal circulations when very high doses of
the prodrug were studied, and the transplacental transfer
of the metabolite was incomplete in our model. Additional
studiesareneededtobettercharacterizethepharmacokinetic
behavior of oseltamivir in pregnancy to assess the need for
dosing adjustments and the eﬀects of the medication on the
developing fetus.
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